Balancing access to BPaLM regimens and risk of resistance

• Author(s): Van Rie, Annelies ; Walker, Timothy ; de Jong, Bouke ; Rupasinghe, Praharshinie ; Rivière, Emmanuel ; Dartois, Véronique ; Sonnenkalb, Lindsay ; Machado, Diana ; Gagneux, Sébastien ; Supply, Philip ; Dreyer, Viola ; Niemann, Stefan ; Goig, Galo ; Meehan, Conor ; Tagliani, Elisa ; Cirillo, Daniela Maria
• Date: 2022
• Persistent ID: http://hdl.handle.net/10362/148974
• Origin: Repositório Institucional da UNL
• Subject(s): Mycobacterium tuberculosis; Multidrug resistance (MDR); Antimycobacterial agents; BPaLM regimens; risk of resistance; RA0421 Public health. Hygiene. Preventive Medicine; RM Therapeutics. Pharmacology; QR Microbiology; T Technology; Infectious Diseases; Health Policy; Pharmacology (medical); SDG 3 - Good Health and Well-being; SDG 12 - Responsible Consumption and Production; SDG 9 - Industry, Innovation, and Infrastructure
• Document Type: Other
• Language: English
• Contributor(s): TB, HIV and opportunistic diseases and pathogens (THOP); Global Health and Tropical Medicine (GHTM); Instituto de Higiene e Medicina Tropical (IHMT); Universidade NOVA de Lisboa; RUN

Description

Funding Information: AVR reports receiving funding from Research Foundation Flanders (Belgium) related to whole-genome sequencing of M tuberculosis. BdJ reports an institutional contract for central laboratory support to the C211 pediatric bedaquiline trial with Janssen and participation in the scientific advisory boards of the Dioraphte foundation and Panacea. PS reports personal consulting fees from Genoscreen. DMC reports receiving grants from European Committee on Antimicrobial Susceptibility Testing (EUCAST) to study epidemiological cut-off values (ECOFFs) in EUCAST-recommenced methods, funding from UNITE4TB to study ECOFF distributions of drugs included in clinical trials, and participating in the TB alliance study on the M tuberculosis lineage 1 distribution. All other authors declare no competing interests.